BENDAMUSTINE HCL
Product Description
DCS Pharma USA
-
Country/Region:Switzerland
-
On CPHI since:2018
Categories
Specifications
DCS Pharma USA
-
Country/Region:Switzerland
-
On CPHI since:2018
More Products from DCS Pharma USA (2)
-
Product BORTEZOMIB
With earlier than expected entry of the generic into the US, the market potential of Bortezomib is expected to increase significantly. Be the first in the market with our technical and regulatory support. REGULATORY STATUS: US-DMF: YES - US-FDA inspection: Q4-2018 - EU-DMF: Submitted Q4-2017 -
Product DAPAGLIFLOZIN
Dapagliflozin inhibits the protein responsible for delivering glucose into the bloodstream. REGULATORY STATUS: US-DMF: YES - US-FDA approval: Expected - EU-DMF: In preparation. www.dcspharma.com/dapagliflozin
DCS Pharma USA resources (1)
-
Brochure PORTFOLIO DCS PHARMA USA
YOUR API EXPERTS: The highest quality, specialized knowledge, and transparency: this is what we bring to active pharmaceutical ingredients.We are your specialists with clearly-defined schedules, extensive high-quality Swiss services, and a global network built up over decades. We focus on a few select therapeutic groups and set the right priorities.Because we’re quality-conscious.

